Stockreport

CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma

Candel Therapeutics, Inc.  (CADL) 
PDF NEEDHAM, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused [Read more]